---
layout: default
title: Bendamustine Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 125
evidence_level: L5
indication_count: 0
---

# Bendamustine Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Bendamustine Hydrochloride: Drug Repurposing Evaluation Report

## One-Sentence Summary

Bendamustine hydrochloride is an alkylating antineoplastic agent used primarily for the treatment of chronic lymphocytic leukaemia (CLL) and indolent B-cell non-Hodgkin lymphoma. The TxGNN model currently has **no predicted new indications** for this drug. The evidence pack contains **significant data gaps** — including missing DrugBank ID, MOA, licence details, and safety information — that must be resolved before any repurposing evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in evidence pack (known: CLL, indolent NHL) |
| Predicted New Indication | None — no TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not available |
| Malaysia Market Status | ✓ Marketed (已上市) |
| Number of Registrations | 10 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

> Currently, no TxGNN prediction has been generated for Bendamustine Hydrochloride, so a mechanistic plausibility assessment cannot be performed.

Based on general pharmacological knowledge, bendamustine is a unique bifunctional alkylating agent that combines properties of both an alkylating agent (nitrogen mustard group) and a purine analogue (benzimidazole ring). This dual mechanism causes DNA cross-linking, strand breaks, and disruption of mitotic checkpoints, leading to apoptosis in rapidly dividing cells. It has demonstrated clinical efficacy in CLL, indolent B-cell NHL, and multiple myeloma.

The absence of a TxGNN prediction may be due to a missing DrugBank ID mapping (currently `null`), which would prevent the drug from being matched within the knowledge graph. **Resolving the DrugBank mapping is a prerequisite** for generating repurposing candidates.

---

## Malaysia Market Information

The evidence pack reports **10 registered licences** with market status "Marketed" (已上市), however all licence detail fields are empty. Licence-level data needs to be re-collected.

| Item | Status |
|------|------|
| Total Licences | 10 |
| Licence Details Available | ✗ Not available — all fields empty |
| Action Required | Re-query NPRA database for complete licence records |

---

## Cytotoxicity

Bendamustine hydrochloride is a known cytotoxic antineoplastic agent (alkylating agent class). The following assessment is based on established pharmacological knowledge, as the evidence pack does not contain DrugBank toxicity data.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Conventional cytotoxic (Bifunctional alkylating agent / Purine analogue hybrid) |
| Myelosuppression Risk | **High** — neutropenia, thrombocytopenia, and anaemia are dose-limiting toxicities |
| Emetogenicity Classification | Low to moderate |
| Monitoring Items | CBC with differential (before each cycle), liver function (ALT, AST, bilirubin), renal function (creatinine, eGFR), infections signs |
| Handling Protection | Must follow cytotoxic drug handling regulations (closed-system transfer, PPE, spill kit) |

---

## Safety Considerations

> Please refer to the package insert for safety information.
>
> **Note:** The evidence pack contains no usable safety data — key warnings, contraindications, and drug–drug interactions are all marked as data gaps. This is classified as a **Blocking** severity gap (DG001) that prevents entry into Stage 1 safety assessment.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN repurposing prediction exists for Bendamustine Hydrochloride, and multiple critical data gaps (DrugBank ID, MOA, safety profile, licence details) prevent any meaningful evaluation. The drug cannot proceed to repurposing assessment in its current state.

**To proceed, the following is needed:**

1. **DrugBank ID mapping** (DG002 — High severity): Query DrugBank API for "Bendamustine" to obtain the DrugBank ID (expected: DB06769) and integrate it into the knowledge graph for TxGNN prediction
2. **Mechanism of action data** (DG002 — High severity): Retrieve detailed MOA, targets, and pathway information from DrugBank
3. **NPRA licence details**: Re-query the NPRA database to populate all 10 licence records with product names, dosage forms, manufacturers, and approved indications
4. **Safety profile** (DG001 — Blocking): Download and parse the package insert PDF from the regulatory authority website to extract key warnings, contraindications, and drug interactions
5. **Re-run TxGNN prediction**: Once the DrugBank ID is mapped, re-execute the knowledge graph and deep learning prediction pipelines to generate repurposing candidates

---

*Disclaimer: This report is for research purposes only and does not constitute medical advice. Any drug repurposing candidates require clinical validation before application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

